Major R&D achivements
| 2010 | The sea lice product AMX®, deltamethrin 10 mg/ml external solution, (former Deltametrina) received a Marketing Autorization (MA) from the Chilean authorities |
| 2010 | The multi-component ISA vaccine ALPHA JECT® 5-1 from PHARMAQ received a provisional marketing authorisation from the Chilean authorities |
| 2010 | PHARMAQ’s first ISA vaccine ALPHA JECT® micro 1 ISA received a provisional marketing authorisation from the Chilean authorities |
| 2009 | Development and approval of the first autogenous Flavobacterium vaccine for Norwegian trout farmers |
| 2009 | Extensive field trial of the first Pangasius vaccine initiated in Vietnam |
| 2009 | PHARMAQ’s pancreas disease vaccine accepted by Norwegian Medicines Authority for special license |
| 2008 | AMX® received a Marketing Autorization (MA) from the UK authorities and the Irish authorities |
| 2008 | MA approved for ALPHA JECT micro® 6 in Norway, the first six-component micro dose vaccine available |
| 2008 | Sales license for ALPHA JECT® micro 2 in Chile, the micro dose vaccine for trout and coho including IPN virus- and SRS components |
| 2008 | Sales license for ALPHA JECT® micro 3 in Chile, the first trivalent SRS micro dose vaccine available |
| 2008 | Launch of the first micro dose vaccine, a trivalent SRS vaccine in Chile |
| 2008 | Positive opinion for ALPHA MARINE® Vibject in the Norwegian market |
| 2008 | MA approved for ALPHA JECT® 3000 in Ireland, Norway, Finland and Iceland through an EU mutual recognition procedure |
| 2007 | Deltametrina (known as ALPHA MAX® in Norway) for bath treatment against salmon lice granted a sales permission in Chile |
| 2007 | Launch of its first generation SRS vaccine in Chile |
| 2007 | Launch of the first oil based vaccine for cod, ALPHA MARINE® Vibject in Norway |
| 2007 | Acquisition of MS 222® the only fully licensed anaesthetic agent for fish in the European Union |
| 2006 | ALPHA MAX® for bath treatment against salmon lice granted a Marketing Authorisation (MA) in Norway |
| 2005 | Sales licenses for two new oil based vaccines specifically developed for Chile |
| 2005 | Field trial license for an oil based vibriosis vaccine to the Norwegian cod industry |
| 2004 | Isolation and propagation of a new virus in Norwegian farmed salmon (HSMIV - Heart and Skeletal Muscle Inflammation Virus) |
| 2004 | Obtained approval in UK for the first virus vaccine for fish - protection against IPNV and furunculosis |
| 2003 | Cod culturing becomes sustainable – water-based triple vaccine against vibriosis widely used by the Norwegian industry |
| 2002 | A second generation six component vaccine available to the Norwegian market |
| 2002 | The first European fish vaccine ever approved by the Canadian authorities |
| 2001 | The first effective vaccine against IPNV introduced in the Chilean market |
| 1998 | ALPHA MAX® for bath treatment against salmon lice available in the Norwegian- and the Faroese market |
| 1997 | The first six component vaccine ever introduced in Norway. Includes protection against IPNV and winter ulcer. |
| 1996 | Vaccination program for sea bass launched in Greece and Turkey |
| 1991 | Introduction of the world’s first oil based fish vaccine offering protection against furunculosis |
| 1987 | The launch of the first vaccine ever against cold water vibriosis - ”saving” the Norwegian salmon industry |
Corporate development
| 2008 | Acquisition of PHARMAQ by Orkla and Kverva is concluded |
| 2008 | PHARMAQ opened Representative Office in Vietnam |
| 2004 | PHARMAQ established 23 July by 'management buy out' of the Aquatic Animal Health business of Alpharma Inc. |
| 2001 | Established office in Puerto Montt, Chile, later to become PHARMAQ AS Chile Ltda. |
| 1999 | Vetrepharm Ltd in UK acquired, later to become PHARMAQ Ltd. |
| 1996 | State-of-the-art GMP production facility for fish vaccines opens in Overhalla, Norway |
| 1994 | Merger of Apothekernes Laboratorium AS and A.L. Labs Inc (owner of Biomed Inc) to form Alpharma Inc. The Aquatic Animal Health Division (AAHD) of Alpharma Inc. was established |
| 1989 | A.L.Labs.Inc, the USA based daughter company of Apothekernes Laboratorium AS, acquires Biomed Inc. |
| 1985 | Apothekernes Laboratorium AS, Norway, commits to fish health and establish its facilities in Tromsø, Norway |